Bayer Confident It Can Cope With Patent Cliff Pain
Executive Summary
The German major noted that the effects of the losses of patent protection on Xarelto and Eylea are still about five years down the line and it expects to be able to soften the blow with some future big-earners from the pipeline and more external deals.